Capital World Investors
EPZM

Capital World Investors’s Epizyme, Inc EPZM Stock Holding History

Capital World Investors’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-384,000
Closed -$10.4M – 555
2014
Q3 		$10.4M Hold
384,000
– – ﹤0.01% 476
2014
Q2 		$11.9M Hold
384,000
– – ﹤0.01% 465
2014
Q1 		$8.74M Buy
384,000
+284,000
+284% +$8.61M ﹤0.01% 480
2013
Q4 		$2.08M Buy
+100,000
New +$2.9M ﹤0.01% 479

Other funds holding EPZM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Capital World Investors's EPZM Position: Q4 2014 in Review

Capital World Investors sold out of Epizyme, Inc (EPZM) in Q4 2014, closing a stake of 384,000 shares — an estimated $10.4M sold.

Capital World Investors first reported a position in EPZM in Q4 2013 and held it in 4 quarters. The position peaked at $11.9M in Q2 2014. 82 funds tracked by Wall St. Rank hold EPZM as of Q4 2014.

  • Capital World Investors reported no remaining Epizyme, Inc position as of Q4 2014 after selling out during the quarter.
  • Capital World Investors sold 384,000 Epizyme, Inc shares in Q4 2014, an estimated $10.4M.
  • Capital World Investors first reported a position in Epizyme, Inc in Q4 2013 and held it in 4 quarters.
  • Capital World Investors's Epizyme, Inc position peaked at $11.9M in Q2 2014.
  • 82 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2014.

Based on Capital World Investors's 13F filing for Q4 2014, filed 13 Feb 2015.